VRTX Stock Recent News

Vertex Pharmaceuticals will pay $4.9 billion to acquire Alpine Immune Sciences. Alpine stock rocketed.

Vertex Pharmaceuticals will acquire therapy developer Alpine Immune Sciences for $65 per share, or about $4.9 billion in cash, the companies said on Wednesday.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals First Quarter 2024 Earnings Call.” The conference call will be webcast live and a link to the webcast can be a.

Vertex Pharmaceuticals is starting a late-stage study for a promising candidate. In a best-case scenario, it could be as successful as the biotech's current top-seller.

The healthcare industry is full of promising opportunities for every type of investor. UnitedHealth Group's established presence spans insurance to managed care services.

Vertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease.

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $420.48, denoting a +0.59% change from the preceding trading day.

Vertex Pharmaceuticals has an impeccable track record of innovation. The company recently reported important clinical progress.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $416.03, indicating a +0.09% shift from the previous trading day.